(HealthDay)—Ligelizumab appears to be a safe and effective treatment option for chronic spontaneous urticaria, according to a study published in the Oct. 3 issue of the New England Journal of Medicine. In a phase 2b dose-finding study, Marcus Maurer, M.D., from Charité-Universitätsmedizin Berlin, and colleagues randomly assigned 382 patients to receive a single 120-mg dose...